



Investor Webinar – iTrack in Practice: Clinical Insights from Dr Mahmoud Khaimi

Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to invite shareholders and interested parties to a webinar with internationally recognised glaucoma specialist Mahmoud A. Khaimi, M.D., on Wednesday, 26 November 2025, at 9:30 am AEDT.

Dr Khaimi will discuss the clinical and practice advantages of the Company's iTrack Advance™ minimally invasive glaucoma surgical device.

Webinar Details

Date: Wednesday, 26 November 2025

Time: 9:30 am AEDT

Presenter: Mahmoud A. Khaimi, M.D.

Registration Link:

https://us02web.zoom.us/webinar/register/WN c8rt8QWXQMKrwH2M- 1rQw

Speaker Bio - Mahmoud A. Khaimi, M.D.

Mahmoud A. Khaimi is the founder and president of <u>Glaucoma Surgeons of Oklahoma</u>. A leading glaucoma and premium cataract surgeon, he is recognised worldwide for his authority in canaloplasty. In 2013, he performed the first ab interno canaloplasty procedure and has since shaped modern canal-based surgery.

His work contributed to the clinical development of Nova Eye's iTrack Advance™ device. He received 405 Magazine's Healthcare Innovator of the Year award in 2023 for this work.

From 2007 to 2024, he served as Clinical Professor at the Dean McGee Eye Institute, University of Oklahoma. He held the James P. Luton Endowed Chair, led Glaucoma Services, and directed the Glaucoma Fellowship program. He moved into private practice in 2024 and founded Glaucoma Surgeons of Oklahoma, a centre focused on advanced glaucoma care.

-ends-

Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.

For more information:

Company
Tom Spurling
Managing Director
+61 417 818 658

tspurling@nova-eye.com

Investors
Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com